Loading viewer...
earnings
Format: PDF earnings
Karyopharm Therapeutics presented first quarter 2022 financial results and business updates on May 5, 2022, featuring commercial highlights for XPOVIO and pipeline updates for selinexor and eltanexor. The presentation covers financial guidance for 2022 net product revenue and R&D/SG&A expenses, along with clinical development progress across multiple myeloma and diffuse large B-cell lymphoma indications.
conference
34 Pages
earnings
30 Pages
KeyCorp
Wesfarmers 2017 Half-Year Results Briefing
earningsearnings
63 Pages
Wesfarmers Limited